Optimisation of the safety and efficacy of protein kinase inhibitors using endogenous and dietary biomarkers

Website
http://purl.org/au-research/grants/nhmrc/GNT1100179

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.

Funded Activity Summary

Many new cancer medicines are part of the 'kinase inhibitor' group of drugs. Although these drugs are effective in treating a range of different cancers, opportunities remain to improve the effectiveness and safety by more intelligently deciding the dose of the drug that a specific individual should receive. The research aims to assess whether the levels of chemicals normally present in the blood of individuals being treated can be used to guide the best dose an individual should receive.

Funded Activity Details

Start Date: 2016

End Date: 2018

Funding Scheme: Project Grants

Funding Amount: $384,360.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Pharmacology and Therapeutics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Related Researchers

No related researchers have been discovered for grant Optimisation of the safety and efficacy of protein kinase inhibitors using endogenous and dietary biomarkers.

Related Organisations

No related organisations have been discovered for grant Optimisation of the safety and efficacy of protein kinase inhibitors using endogenous and dietary biomarkers.